Business

Emergent BioSolutions announced that it has signed an agreement to acquire marketing rights to Hikma Pharmaceuticals’ Kloxxado naloxone nasal spray in the US and Canada. Kloxxado, which delivers an 8 mg dose, was approved by the FDA for the reversal of opioid overdose in September 2021. Emergent previously acquired Narcan nasal spray, which delivers a 4 mg dose of … [Read more...] about Emergent BioSolutions acquires US and Canadian rights to Hikma’s Kloxxado naloxone nasal spray

Intranasal vaccine developer Leyden Laboratories announced the closing of a $70 million funding round, with proceeds going to support development of prophylactic nasal sprays based on the company's "Mucosal Protection Platform." Leyden Labs, which initiated a Phase 1 trial of its lead candidate, PanFlu intranasal CR9114 anti-hemagglutinin stem human antibody, in … [Read more...] about Leyden Labs raises $70 million for development of its intranasal vaccine platform

Aridis Pharmaceuticals said that "an undisclosed pharmaceutical company" has agreed to pay $6.5 million plus annual royalty payments for Aridis' AR-501 nebulized gallium for the treatment of chronic lung infections in patients with cystic fibrosis. Aridis said that it expects to receive 50% of the upfront payment by the end of the first quarter of 2025 and the other … [Read more...] about Aridis announces that an unnamed pharma company has agreed to acquire AR-501 inhaled gallium

Intranasal drug developer Orexo and Swedish vaccine developer Abera Bioscience have announced that they will collaborate on development of intranasal dry powder vaccines based on Orexo's AmorphOX powder engineering technology and Abera's vaccine platform, starting with an influenza vaccine. Abera will fund the project using grant money it has received from the … [Read more...] about Orexo and Abera partner on development of intranasal dry powder vaccines

Qnovia announced that it has raised $16 million in Series B financing for development of its QN-01 nicotine inhaler for smoking cessation in the UK. In the US, the FDA recently approved Qnovia's IND for a new Phase 1 study of QN-01, which is delivered via a device based on the company's RespiRx vibrating mesh nebulizer technology. According to the announcement, … [Read more...] about Qnovia raises $16 million for continued development of QN-01 inhaled nicotine for smoking cessation

Virpax Pharmaceuticals announced the extension of a research and development agreement with an institute of the National Institutes of Health (NIH) related to the company's NES100 enkephalin nasal spray for the treatment of acute and chronic pain. NES100 is based on molecular envelope technology (MET) licensed from Nanomerics for delivery across the blood-brain … [Read more...] about Virpax announces extension of NCATS R&D agreement for NES intranasal enkephalin

Pulmatrix has announced a planned merger with biopharma Cullgen, which is developing oral protein degraders for the treatment of various indications. In anticipation of the merger, Pulmatrix says that it will divest inhalation assets, including PUR1800 inhaled dry powder narrow spectrum kinase inhibitor, PUR3100 inhaled dry powder DHE, and patents related to the … [Read more...] about Pulmatrix agrees to merge with Cullgen and will divest inhalation assets

Danish pharma company ALK says that it is paying ARS Pharmaceuticals $145 million up front and up to $320 million in potential milestone payments plus royalties for the rights to neffy intranasal adrenaline (epinephrine) everywhere except the US, Australia, New Zealand, Japan, and China. In addition to the marketing rights to neffy for the treatment of anaphylaxis, … [Read more...] about ALK acquires rights to ARS’s neffy adrenaline (epinephrine) nasal spray in much of the world